DarbeLus
A Phase II Study of Luspatercept Plus Darbepoetin Alfa in SF3B1 Wild Type Lower-risk Myelodysplastic Syndromes
What's the purpose of the trial?
This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in SF3B1 wild type, lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
Trial status
Accepting patients
Phase
Phase 2
Enrollment
60
Last Updated
Participating Centers
There are 3 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Darbepoetin Alfa is a bone marrow stimulant used to treat anemia caused by kidney failure or chemotherapy.
- Luspatercept is an agent that helps your bone marrow finish making red blood cells that have started to form.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.